C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 39/35 (2006.01) C07K 14/435 (2006.01) C12N 9/64 (2006.01) C12N 15/57 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2309885
The present invention provides a novel treatment for allergy comprising the provision of a recombinant allergen with reduced enzymatic activity. Vaccines comprising said mutant allergens stimulate a Th1-type immune response in allergic or naïve individuals, thereby reducing the potential for an allergic response upon contact with wild-type allergen. Preferably said allergen is DerP1.
La présente invention porte sur un nouveau traitement des allergies consistant à obtenir des allergènes recombinés à activité enzymatique réduite. Les vaccins comprenant ces allergènes mutants stimulent une réponse immune de type Th1 chez les individus allergiques ou novices, ce qui réduit le potentiel d'une réponse allergique lors du contact avec un allergène de type sauvage. L'allergène est de préférence DerP1.
Bollen Alex
Bruck Claudine
Jacobs Paul
Massaer Marc
Borden Ladner Gervais Llp
Smithkline Beecham Biologicals S.a.
LandOfFree
Recombinant allergen with reduced enzymatic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant allergen with reduced enzymatic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant allergen with reduced enzymatic activity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1416849